Predict your next investment

CONSUMER PRODUCTS & SERVICES | Clothing & Accessories / Accessories

See what CB Insights has to offer


Acquired | Acquired





About Sauflon Pharmaceuticals

Sauflon is a global manufacturer of contact lenses and solutions, offering the widest range of contact lenses and aftercare products anywhere in the world. In addition to aftercare solutions, Sauflon manufactures an extensive range of contact lenses including the latest generation silicone hydrogel lenses. Available in daily disposable and reusable modalities, the clariti family of lenses is positioned to help Eye Care Professionals provide the healthiest and most comfortable lenses to all of their patients.

Sauflon Pharmaceuticals Headquarter Location

49-53 York St

Twickenham, TW1 3LP,

United Kingdom

+44 20 8322 4200

Latest Sauflon Pharmaceuticals News

UPDATE: Oppenheimer Initiates Coverage On Cooper Companies

Dec 16, 2014

The Cooper Companies Misses Q4 Expectations Oppenheimer initiated coverage on Cooper Companies Inc (NYSE: COO ) Tuesday with an Perform rating and $170 price target. Analysts Steven Lichtman and Steven Reiman noted that “COO's subsidiary, CooperVision (81 percent '14 rev. ), is the world's third largest manufacturer of soft contact lenses and has been a market share gainer as it has transitioned from a specialty manufacturer to full-market provider. “COO is looking to continue this momentum as it leverages its acquisition of UK-based Sauflon Pharmaceuticals to build a stronger presence in the fast growing single-use lens market.” Lichtman commented that the “single-use market is projected to be the fastest growing lens market (8-9 percent CAGR through '19) driven primarily by increased adoption in the US. COO has historically been under-indexed in this segment but is making aggressive moves to capture share in this $3B market highlighted by the 6/14 Sauflon acquisition.” The analyst noted cited three major risks: “1) Competition. JNJ and Alcon/CIBA (Novartis) have strong presence in the optometrist's office. 2) US Sauflon adoption. Sauflon has relatively low name recognition in the US. 3) Foreign currency. COO has significant FX exposure and does not hedge.” Cooper Companies recently traded at $156.09, up 0.08 percent. Latest Ratings for COO

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sauflon Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sauflon Pharmaceuticals is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.